Melanoma DNA vaccine - Oxxon Therapeutics

Drug Profile

Melanoma DNA vaccine - Oxxon Therapeutics

Alternative Names: Hi-8 MEL; MEL1 immunotherapy - Oxxon; pSG2.MEL3/MVA.MEL3

Latest Information Update: 15 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxxon Therapeutics
  • Developer Oxford BioMedica
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 15 Sep 2015 No recent reports on development identified - Phase-II for Malignant melanoma in Germany and United Kingdom (unspecified route)
  • 05 Jun 2006 Data presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2006) have been added to the Cancer therapeutic trials section
  • 16 May 2005 Phase-II clinical trials in Malignant melanoma in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top